Maravai LifeSciences Faces Class Action Lawsuit: Key Details for Investors

LOS ANGELES, April 28, 2025 — The Schall Law Firm, a national shareholder rights litigation firm, has announced a class action lawsuit against Maravai LifeSciences Holdings, Inc. (“Maravai” or “the Company”) MRVI. This case addresses violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5 established by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between August 7, 2024 and February 24, 2025 are encouraged to contact the firm before May 5, 2025.

If you are a shareholder who has incurred losses, you should consider participating.

You may also contact Brian Schall of the Schall Law Firm at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, by calling 310-301-3335. Additionally, you can reach the firm through their website or by email at [email protected].

As of now, the class has not been certified. Until such certification occurs, affected investors do not have legal representation through this case. You may choose to do nothing and remain an absent class member.

Allegations Against Maravai

The Complaint alleges that Maravai made false and misleading statements to the market. The Company reportedly failed to maintain adequate internal controls over financial reporting, improperly recognized revenue from certain transactions in fiscal 2024, and overstated its goodwill. As a result of these inaccuracies, the Company’s public statements were deemed false and materially misleading throughout the class period. Once the market absorbed the truth about Maravai, investors suffered financial damages.

Next Steps for Investors

Affected shareholders are encouraged to join the lawsuit to seek recovery for their losses.

The Schall Law Firm focuses on representing investors worldwide in securities class action lawsuits and shareholder rights litigation.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
Office: 310-301-3335
Email: [email protected]